BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 11, 2021
View Archived Issues
UCART-19 shows antileukemic activity in heavily pretreated pediatric and adult patients
Read More
JMX-0207 inhibits Zika virus both in vitro and in vivo
Read More
Inhaled phage therapy YPT-01 enters phase I/II trial to treat P. aeruginosa in cystic fibrosis
Read More
FDA clears IND for phase I study of DA-01 in advanced Parkinson's disease
Read More
CARs with switches
Read More
FDA issues clinical hold letter related to an IND for NL-201
Read More
Positive phase IIb data presented for DBI-001 in tinea pedis
Read More
Dana-Farber Cancer Institute patents EGFR allosteric inhibitors
Read More
Bristol Myers Squibb discloses new FPR2 agonists
Read More
Calithera Biosciences presents CD73 inhibitors
Read More
Indian researchers patent new lipoxygenase inhibitors
Read More
Antibodies target fibrotic and autoimmune diseases
Read More
CAR-MICA/B immunotherapy controls hematopoietic and solid tumor progression in vivo
Read More
AMMS synthesizes new adenosine A2A receptor agonists
Read More
Discovery of non-sugar-derived OGA inhibitors for neurodegenerative disorders
Read More
U.K. approval of COVID-19 Vaccine Moderna
Read More
Tocilizumab to be used in U.K. for ICU patients with COVID-19
Read More
Open-label study data show patients treated with LB-1148 had shorter hospital stay
Read More
Preclinical data presented for CD30-targeting CAR T cells as lymphoma immunotherapy
Read More
Ultragenyx updates gene therapy program progress
Read More
E.U. approval for Xofluza for treatment and postexposure prophylaxis of influenza
Read More
Celon reports topline phase II data on Falkieri in bipolar depression
Read More
Ideaya submits IND for phase I evaluation of MAT2A inhibitor IDE-397
Read More
Phase II TRAILBLAZER-ALZ trial of donanemab in Alzheimer's meets primary endpoint
Read More
Cara opens phase II trial of oral difelikefalin for notalgia paresthetica pruritus
Read More